Subjective, patient-reported data on lived experiences should always be considered in the care of chronic conditions like multiple sclerosis (MS), according to a recent presentation. In a survey, many people with MS reported feeling that their lived experiences aren’t given enough consideration during visits with their care providers, and…
News
The understanding and management of neuropsychiatric symptoms such as depression and cognitive difficulties in multiple sclerosis (MS) have advanced substantially, but there’s more progress to be made, said Anthony Feinstein, PhD, a neuropsychiatrist and professor of psychiatry at the University of Toronto. Feinstein, who delivered the June Halper Memorial Lecture…
Advocates around the globe are coming together this Saturday, May 30, for World MS Day to push for better care, earlier diagnoses, and increased awareness for people living with multiple sclerosis (MS). Launched in 2009 by the MS International Federation (MSIF), a coalition of MS advocacy groups,…
The Consortium of Multiple Sclerosis Centers (CMSC) 2026 annual meeting kicks off today in Charlotte, North Carolina, bringing together clinicians, researchers, rehabilitation specialists, and patient advocates for three days of discussions on the latest advances in multiple sclerosis (MS) care and research. At this year’s meeting, CMSC is…
Patient enrollment is complete in a Phase 2a clinical trial testing Tiziana Life Sciences‘ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), a form of multiple sclerosis (MS) with limited treatment options. “Reaching full enrollment in this landmark study is a testament to the strong…
Many women with multiple sclerosis (MS) have misconceptions or a lack of information about how the disease may affect pregnancy and childbirth, and healthcare providers rarely broach the topic, a study found. The findings suggest that women with MS may be making decisions about family planning based…
The neuroprotective effects of exercise in multiple sclerosis (MS) may be aided by the irisin hormone. A study showed irisin reduced nerve cell loss and eased clinical symptoms in a mouse model of the disease, making the hormone a potential new therapeutic target. And unlike existing MS therapies…
Using psychoactive drugs such as alcohol, caffeine, nicotine, cannabis, or opioids may help ease certain symptoms of multiple sclerosis (MS) — but many of these substances can make other MS symptoms worse, a study found. The researchers also found that the specific symptoms a patient experiences significantly affect…
The two main mouse models used to study myelin damage in multiple sclerosis (MS) each replicate important but distinct biological features of the disease — but both fall short of capturing its full biological complexity, a new study shows. The findings suggest that each of these two models may…
Enrollment is half complete in an ongoing clinical study at Massachusetts General Hospital (MGH) testing whether a PET imaging tracer can reliably measure myelin damage in people with multiple sclerosis (MS). The Phase 1 study (NCT04699747) is recruiting about 60 people — healthy adults and MS patients — who…
Leaders in multiple sclerosis (MS) research and care are preparing to gather in Charlotte, North Carolina, for the Consortium of MS Centers (CMSC) annual meeting, with this year marking the organization’s 40th anniversary. Multiple Sclerosis News Today sat down with the consortium’s CEO, Kathleen Costello, to discuss the…
Tiziana Life Sciences‘ experimental nasal spray foralumab continues to show signs that it may help slow disability progression and ease fatigue in people with nonactive secondary progressive multiple sclerosis (SPMS), according to new data from an expanded access program (EAP). Fourteen people with nonactive SPMS have been using…
The presence of multiple asymptomatic spinal cord lesions — areas of damage, as captured by imaging scans — is associated with about a twofold higher risk of developing multiple sclerosis (MS) for people with a first episode of myelitis, or inflammation of the spinal cord, a new study suggests.
A 24-hour livestream to raise funds for multiple sclerosis care and research will feature musicians, comedians, and actors, including cast members from popular TV shows such as “That ’70s Show” and “Sabrina the Teenage Witch.” Comedian John Poveromo will host the…
Liberate Bio’s investigational CAR-M cell therapy LIB820 may help successfully eliminate disease-driving B-cells in autoimmune diseases such as multiple sclerosis (MS) without causing severe side effects, according to new preclinical data. The therapy is designed to genetically engineer two types of immune cells — monocytes and macrophages — within…
Cantex Pharmaceuticals and Headlamp Health are teaming up to fast-track an oral treatment for the debilitating depression and fatigue that affects many people living with multiple sclerosis (MS). The partnership centers…
In stable relapsing-remitting multiple sclerosis (RRMS), higher physical disability scores and brain volume loss on MRI are stronger indicators of cognitive impairment than common blood biomarkers. A new study found that while blood tests often fail to reflect mental decline, MRI scans and standard disability tests can successfully identify…
28bio has developed miniature brain models to help evaluate potential treatments that aim to repair myelin, the fatty coating around nerve fibers that is damaged in multiple sclerosis (MS) and other conditions. The CNS-3D Myelinated Organoids contain multiple brain cell types, including nerve cells and myelin-producing oligodendrocytes.
Two commonly used disease-modifying treatments seem to be equally effective for most people with late-onset multiple sclerosis (LOMS), according to a real-world analysis. Anti-CD20 therapies, designed to reduce immune cells that produce disease-driving antibodies, and S1P receptor modulators, which work by preventing pro-inflammatory immune cells from reaching the brain,…
A new type of MRI scan may be able to distinguish active multiple sclerosis (MS) lesions from chronic lesions — without the need for injected contrast dye — while also offering clues about how lesions may evolve over time, a new study reports. By combining artificial intelligence with…
Decode Health and Circular Genomics are partnering to use artificial intelligence (AI) to identify patterns in circular RNA — stable genetic molecules able to signal disease — that may help diagnose multiple sclerosis (MS) earlier and monitor its progression over time. The collaboration brings together Circular Genomics’…
The U.S. Food and Drug Administration (FDA) has formally agreed that the design and planned analysis of an upcoming Phase 3 trial testing privosegtor in people with optic neuritis could support a future application seeking the therapy’s approval if the trial succeeds. Optic neuritis, or inflammation of the…
The U.S. Food and Drug Administration (FDA) has approved the infusion therapy Ocrevus (ocrelizumab) for treating children with relapsing-remitting multiple sclerosis (RRMS) who are ages 10 and older and weigh at least 55 pounds (25 kg). The approval makes Ocrevus the second-ever therapy to win formal FDA approval…
More than 5,000 cyclists took part in the 2026 Bike MS: ACC Texas MS 150 event, a two-day fundraising ride with proceeds aiming to support research and services for people with multiple sclerosis (MS). Part of the Bike MS initiative, the Texas ride is the largest fundraising…
Menstrual fluid collected from tampons could one day provide a simple, noninvasive way to measure a biomarker of nerve damage and potentially track disease activity in neurological conditions such as multiple sclerosis (MS). Researchers at Nextgen Jane, in collaboration with Siemens Healthineers…
The first participant has been dosed in an investigator-initiated Phase 2 clinical trial testing Neuraly‘s experimental medication pegsebrenatide as a potential treatment for progressive forms of multiple sclerosis (MS). Called TAG-MS (NCT07497399), the study is being led by Ellen Mowry, MD, at…
A pilot clinical trial in the U.S. is enrolling people with relapsing-remitting multiple sclerosis (RRMS) to test Setpoint Medical’s implantable nerve stimulation device, which is designed to reduce inflammation and promote myelin repair. The trial (NCT06796504) is enrolling up to 60 people, ages 22-50, and will evaluate…
People in the U.S. with commercial insurance wait nearly 50 days on average for a first visit to neurologist, and average wait times are significantly longer, by about four days, for those with multiple sclerosis (MS), a study found. The number of neurologists in a given area didn’t influence…
Having a second autoimmune disease does not accelerate disability progression in people with multiple sclerosis (MS), according to a large single-center study. Among 1,230 MS patients followed over time, those living with an additional autoimmune condition that doesn’t affect the nervous system reached disability milestones at the same rate…
The Multiple Sclerosis Association of America (MSAA) will host its 12th annual Improving Lives Benefit on May 7, bringing the multiple sclerosis (MS) community together to raise funds and recognize advocates and innovators working to improve care and support. The fundraiser will take place at the Switch…
Recommended Posts
- Our bodies often tell us what we need to know — if we’re willing to listen
- CMSC 2026: MS patients often downplay symptoms to their doctors: Survey
- Thriving with MS: Finding joy and purpose after my diagnosis
- Contributing to better quality of MS care at this year’s CMSC meeting
- I do a lot of pretending while living with MS